Veracyte Stock Pattern Recognition Breakaway

VCYT Stock  USD 32.78  0.00  0.00%   
The pattern recognition module provides an execution environment for Breakaway recognition and related indicators on Veracyte. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for Veracyte.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. This analysis covers forty-seven data points across the selected time horizon. The function did not return any valid pattern recognition events for the selected time horizon. Veracyte breakaway pattern warns about a short-term trend reversal.

Veracyte Technical Analysis Modules

Most technical analysis of Veracyte help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Veracyte from various momentum indicators to cycle indicators. When you analyze Veracyte charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. The stock overview for Veracyte summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 1.95, profit margin of 12.83%. Veracyte has a market cap of 2.55 B, ROE of 5.34%.

Methodology

Unless otherwise specified, financial data for Veracyte is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Veracyte (USA Stocks:VCYT) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Veracyte has active sell-side coverage. Source-validated coverage currently shows 12 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 6 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, Jefferies, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Ellen Johnson - Member of Macroaxis Editorial Board
Last reviewed on February 23rd, 2026

Be your own money manager

Portfolio analytics tied to Veracyte help investors review performance in context instead of judging the holding in isolation. The stronger process keeps portfolio transparency high without forcing constant manual review of every holding.

Generate Optimal Portfolios

Align your risk and return expectations

Risk tolerance and time horizon inputs allow Macroaxis optimization to estimate acceptable risk levels. The output provides a structured risk context for return targets.

Additional Tools for Veracyte Stock Analysis

Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Transaction History
View history of all your transactions and understand their impact on performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
CEOs Directory
Screen CEOs from public companies around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals